The triplet combination of VEN, AZA, and ivosidenib (an IDH1 inhibitor) is being tested in a phase I/II trial for IDH1-mutated AML patients, either naive or R/R (NCT03471260). Here, IDH1 is linked to acute myeloid leukemia.